In contrast to SCCOHT, SMARCA4-deficient NSCLC cells (H1299, H2030, H1703, A427) can better tolerate restoration of SMARCA4 expression, which results in drug resistance to CDK4/6 inhibition, regardless of KRAS mutation status (Fig. 6a, b and Supplementary Fig. 7d, e). Here, CDK4 is linked to non-small cell lung carcinoma.